Incisive Genetics has developed a novel delivery platform of functional CRISPR components. Until now the core problem facing all gene therapy treatments has been delivery —incumbent technologies are one-shot therapies, require higher doses, and are inefficient. The Incisive Delivery System comprises a novel formulation of LNP which enables the encapsulation of functional CRISPR components and multiple therapies with the same base components.